SR 271425

Drug Profile

SR 271425

Alternative Names: BCN 326862; Cytolytic thioxanthone; SR271425; Thioxanthone

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi-Synthelabo
  • Developer sanofi-aventis; Sanofi-Synthelabo
  • Class Antineoplastics
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Leukaemia; Lymphoma; Solid tumours

Most Recent Events

  • 27 Feb 2009 Discontinued - Phase-I for Solid tumours in Europe (IV-infusion)
  • 26 Jul 2005 Data presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO-2005) have been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,,
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top